RT Journal Article SR Electronic T1 Recent advances in diagnosis and management of hypertrophic cardiomyopathy JF Heart Asia JO Heart Asia FD BMJ Publishing Group Ltd, British Cardiovascular Society and Asia Pacific Heart Association SP 16 OP 19 DO 10.1136/ha.2008.000216 VO 1 IS 1 A1 B B Siswanto A1 R Aryani YR 2009 UL http://heartasia.bmj.com/content/1/1/16.abstract AB Hypertrophic cardiomyopathy (HCM) is characterised by a thickened but non-dilated left ventricle in the absence of another cardiac or systemic condition capable of producing the magnitude of hypertrophy evident. It is the most common familial genetic disease of the heart (1/500 to 1/1000), as well as the most common cause of sudden cardiac death in young people and athletes. Survival rates of patients with HCM have improved from the 1960s onwards. Natural history in patients with HCM might vary from developing severe heart failure or atrial fibrillation, some die suddenly, often at a young age and in the absence of previous symptoms. Because of its heterogeneous clinical course and expression, HCM frequently presents uncertainty and represents a management dilemma to cardiovascular specialists and other practitioners.